The canine prostate cancer cell line CHP-1 shows over-expression of the co-chaperone small glutamine-rich tetratricopeptide repeat-containing protein α.

Abstract

Although androgen therapy resistance and poor clinical outcomes are seen in most canine prostate cancer cases, there are only a few tools for analysing canine prostate cancer by using a cell biological approach. Therefore, to evaluate androgen-independent neoplastic cell growth, a new canine prostate cancer cell line (CHP-1) was established in this study. CHP-1 over-expressed the co-chaperone small glutamine-rich tetratricopeptide repeat-containing protein α (SGTA), which is over-expressed in human androgen-independent prostate cancer. The CHP-1 xenograft also showed SGTA over-expression. Although CHP-1 shows poor androgen receptor (AR) signalling upon dihydrotestosterone stimulation, forced expression of AR enabled evaluation of AR signalling. Taken together, these results suggest that CHP-1 will be a useful model for investigating the pathogenesis of androgen-dependent and androgen-independent canine prostate cancer.

• Authors: D Azakami, R Nakahira, Y Kato, M Michishita, M Kobayashi, E Onozawa, M Bonkobara, M Kobayashi, K Takahashi, M Watanabe, K Ishioka, T Sako, K Ochiai, T Omi
• Journal: Veterinary and comparative oncology (Vet Comp Oncol) Vol. 15 Issue 2 Pg. 557-562 (Jun 2017) ISSN: 1476-5829 [Electronic] England
• PMID: 26762899 (Publication Type: Journal Article)
• Copyright: © 2016 John Wiley & Sons Ltd.

Chemical References

• Carrier Proteins
• Glutamine

Topics

• Animals
• Carrier Proteins (metabolism)
• Cell Line, Tumor
• Dog Diseases (metabolism, pathology)
• Dogs
• Glutamine
• Male
• Mice, Nude
• Neoplasm Transplantation
• Prostate (metabolism, pathology)
• Prostatic Neoplasms (metabolism, pathology, veterinary)
• Reverse Transcriptase Polymerase Chain Reaction (veterinary)
• Tetratricopeptide Repeat